<DOC>
	<DOCNO>NCT00145925</DOCNO>
	<brief_summary>The purpose study provide information risk benefit routine blood pressure lower ( regardless blood pressure level ) , intensive lower blood glucose level , patient Type 2 diabetes high risk cardiovascular event . The major outcome study cardiovascular event ( heart attack , stroke die result cardiovascular disease ) , well new worsen diabetic eye kidney disease .</brief_summary>
	<brief_title>Blood Pressure Glucose Lowering Prevention Vascular Disease High Risk Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Patients type 2 diabetes increase risk macrovascular microvascular disease , reduce control raise blood pressure hypertensive individual . Intensive glycaemic control also show reduce microvascular disease , effect macrovascular disease remain uncertain . This study examine hypothesis blood pressure lower ( ACE inhibitor-diuretic combination ) intensive glycaemic control ( sulphonylurea-based regimen ) high-risk individual type 2 diabetes ( include hypertensive non-hypertensive subject ) reduce incidence macrovascular microvascular disease . The study 2 x 2 factorial randomise controlled trial include 11,140 adult type 2 diabetes elevate risk vascular disease . Following 6 week open label perindopril-indapamide combination , eligible individual randomise continue perindopril-indapamide matching placebo , intensive gliclazide MR-based glucose control regimen ( aim HbA1c 6.5 % low ) usual guidelines-based therapy . Primary outcome , first , composite non-fatal stroke , non-fatal myocardial infarction cardiovascular death , second , composite new worsen nephropathy diabetic eye disease . These primary outcome analyse jointly separately . The average duration treatment follow-up 5.5 6 year . The study conduct 214 centre Australasia , Asia , Europe North America . ADVANCE design provide reliable evidence balance benefit risk confer blood pressure lower therapy intensive glucose control therapy high-risk diabetic patient , irrespective initial blood pressure glucose level .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Indapamide , perindopril drug combination</mesh_term>
	<mesh_term>Indapamide</mesh_term>
	<mesh_term>Perindopril</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>1 . A diagnosis type 2 diabetes mellitus first make age 30 year old 2 . Age 55 year old entry 3 . Ability provide inform consent 4 . A substantially elevate risk cardiovascular disease , indicate : A history major macrovascular disease define one : stroke , myocardial infarction , hospital admission transient ischaemic attack , hospital admission unstable angina , coronary artery bypass graft , percutaneous transluminal coronary angioplasty ( without stenting ) , peripheral revascularisation ( angioplasty surgery ) amputation secondary vascular disease A history major microvascular disease define one nephropathy ( albumin : creatinine ratio &gt; 300ug/mg ) , retinal photocoagulation therapy , proliferative retinopathy ( new blood vessel disc elsewhere , vitreous haemorrhage , preretinal haemorrhage , fibrous proliferation disc elsewhere ) , macular oedema ( retinal thickening within one disc diameter macular centre ) blindness either eye ( correct visual acuity 6/60 worse , persist three month ) know due nondiabetic cause A first diagnosis type 2 diabetes make 10 year prior entry Another major risk factor vascular disease define one : current daily cigarette smoking , total cholesterol great 6.0 mmol/l ( without cholesterol lower treatment ) , HDL cholesterol &lt; 1.0 mmol/l , microalbuminuria ( albumin : creatinine ratio 30300ug/mg ) Age 65 year 1 . A definite contraindication treatment ACE inhibitor thiazidelike diuretic 2 . A specific indication treatment ACE inhibitor perindopril 24 mg daily ( see also section 5.2.3 ) thiazidelike diuretic 3 . A definite specific indication treatment gliclazide haemoglobin A1c control target 6.5 % less 4 . A definite contraindication treatment gliclazide haemoglobin A1c control target 6.5 % less 5 . A definite indication longterm fulldose bedtime insulin therapy 6 . Participation trial within month prior Registration Visit current participation another trial Other potential reason ineligibility include : High probability nonadherence study treatment followup Current clinical instability ( e.g . major cerebral coronary event sightthreatening retinopathy macular oedema within previous week ) Life threaten nonvascular disease diabetes complication Moderate severe dementia Major disability likely prevent regular attendance study clinic Final decision eligibility make discretion study investigator potential study participant , light requirement guidance local ethic committee regulatory body .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Stroke</keyword>
	<keyword>MI</keyword>
</DOC>